Future Fields

About Future Fields

Future Fields utilizes its EntoEngine™ platform to produce custom recombinant proteins using fruit flies, enabling the scalable manufacturing of difficult-to-express proteins. This approach addresses the challenges of high production costs and environmental impact associated with traditional protein synthesis methods.

```xml <problem> Traditional methods of recombinant protein production often face challenges related to scalability, high costs, and environmental concerns, particularly when dealing with difficult-to-express proteins. These limitations can hinder research and development efforts across various industries. </problem> <solution> Future Fields offers the EntoEngine™ platform, a novel biomanufacturing approach that leverages fruit flies for the production of custom recombinant proteins. This technology enables the scalable and cost-effective manufacturing of proteins that are traditionally difficult to express using conventional methods. By utilizing fruit flies as bioreactors, Future Fields provides a sustainable alternative to traditional protein synthesis, reducing both production costs and environmental impact. The platform aims to make previously unmakeable proteins accessible for a variety of applications. </solution> <features> - EntoEngine™ platform utilizing fruit flies as bioreactors for protein production - Scalable manufacturing of difficult-to-express recombinant proteins - Sustainable and cost-effective alternative to traditional protein synthesis methods - Custom protein production services tailored to specific research and development needs </features> <target_audience> The primary target audience includes researchers, biotech companies, and other organizations requiring access to high-quality, difficult-to-express recombinant proteins for various applications. </target_audience> ```

What does Future Fields do?

Future Fields utilizes its EntoEngine™ platform to produce custom recombinant proteins using fruit flies, enabling the scalable manufacturing of difficult-to-express proteins. This approach addresses the challenges of high production costs and environmental impact associated with traditional protein synthesis methods.

Where is Future Fields located?

Future Fields is based in Edmonton, Canada.

When was Future Fields founded?

Future Fields was founded in 2018.

How much funding has Future Fields raised?

Future Fields has raised $14.4M.

Location
Edmonton, Canada
Founded
2018
Funding
$14.4M
Employees
44 employees
Investors
Bee PartnersToyota VenturesKeiki Capital

Future Fields

10
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

Future Fields utilizes its EntoEngine™ platform to produce custom recombinant proteins using fruit flies, enabling the scalable manufacturing of difficult-to-express proteins. This approach addresses the challenges of high production costs and environmental impact associated with traditional protein synthesis methods.

futurefields.io5K+
Founded 2018Edmonton, Canada

Funding

No specific funding rounds found.

Total Funding

$14.4M

Backed by

Bee PartnersKeiki CapitalToyota Ventures

Team (40+)

No team information available.

Company Description

Problem

Traditional methods of recombinant protein production often face challenges related to scalability, high costs, and environmental concerns, particularly when dealing with difficult-to-express proteins. These limitations can hinder research and development efforts across various industries.

Solution

Future Fields offers the EntoEngine™ platform, a novel biomanufacturing approach that leverages fruit flies for the production of custom recombinant proteins. This technology enables the scalable and cost-effective manufacturing of proteins that are traditionally difficult to express using conventional methods. By utilizing fruit flies as bioreactors, Future Fields provides a sustainable alternative to traditional protein synthesis, reducing both production costs and environmental impact. The platform aims to make previously unmakeable proteins accessible for a variety of applications.

Features

EntoEngine™ platform utilizing fruit flies as bioreactors for protein production

Scalable manufacturing of difficult-to-express recombinant proteins

Sustainable and cost-effective alternative to traditional protein synthesis methods

Custom protein production services tailored to specific research and development needs

Target Audience

The primary target audience includes researchers, biotech companies, and other organizations requiring access to high-quality, difficult-to-express recombinant proteins for various applications.

Sources:

This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.